4 articles
The global cannabis market currently promotes 'wellness' through cannabinoids, yet clinical data reveals a high-risk profile for patients with Bipolar Disorder (BD). To move past industry marketing, we must examine the intersection of the Endocannabinoid System (ECS), neurotransmitter signaling, and genetic susceptibility. For those living with BD, understanding these mechanisms may assist in mitigating risk.
Managing bipolar disorder involves protecting the delicate internal chemistry that keeps you grounded. If you are considering cannabis as part of your routine, it is vital to look past anecdotal relief and examine the clinical reality. Using substances while living with a mood disorder is a high-stakes balancing act.
Post-traumatic stress disorder (PTSD) creates a state of constant high alert. The nervous system may feel perpetually stuck in 'fight or flight,' which can result in hyperarousal, intrusive thoughts, and persistent sleep disturbances. While cannabis is not a remedy for all, it may serve as an effective tool to assist in regulating stress—provided it is used with intention and precise dosing.
Modern neuroscience is moving past the era of viewing cannabis simply as an intoxicant. Instead, we are beginning to understand it as a potential tool for modulating the Endocannabinoid System (ECS) and its interaction with serotonin and dopamine. For those navigating the intersection of mental health and cannabis, the focus is shifting from simple potency to the biological mechanics of how these compounds may influence emotional regulation.